Most regenerative treatments offered by clinics in Japan are self-pay, which in Japanese terms means private medical care (jiyu shinryo). The patient pays the full price, and the clinic sets it. Japan's public health insurance generally does not pay for these treatments, and the rules on combining insured and uninsured care are complex, so a self-pay procedure should be assumed to be self-pay even when it sits next to covered care. Approved regenerative products are a different case: once a product is approved and listed, it can enter the insurance system.

This article explains the difference, why it matters for your budget, and what it means for an international patient.

Insured care and private care

Japan runs a national insurance system. Care that is listed in the national insurance schedule is covered, and the patient pays a share at the point of care. Which items are listed, and at what fee, is decided through the national insurance schedule.

The two kinds of care compare as follows:

Insured care Private (self-pay) care
What it covers Treatments on the insurance list, such as standard examinations, drugs and surgery Treatments not on the list, including many clinic-based cell treatments
How price is set National fee and drug price schedules Set by the clinic
Who pays The patient pays a share; insurance pays the rest The patient pays the full amount
Evidence threshold Efficacy and safety generally confirmed before listing Not tied to insurance review

The last row needs a note. Self-pay care is not unregulated. Regenerative treatments by clinics fall under the Act on the Safety of Regenerative Medicine, which requires a filed provision plan and committee review. But that process checks safety and the clinic's capacity to deliver the treatment. It is not an insurance decision, and it does not set the price.

Why combining insured and self-pay care is complicated

Patients often ask whether the insured parts of a visit can be billed to insurance while only the cell treatment is paid privately. The rules on combining insured and uninsured care are complex and depend on the specific treatment and setting, so this should be confirmed case by case. In general, treatments outside insurance are charged separately by the clinic, and a clinic should be able to tell you exactly which items are self-pay and which, if any, are covered.

A person reaches into a clear bin on a wall-mounted medical supply dispenser.

Approved products are different

A regenerative product that has been approved under the drug and device law is a separate case. The Act itself excludes approved products used within their approved conditions from its scope (Article 2 of the Act). Those products fall under pharmaceutical law. Whether and when a product is covered by insurance depends on its listing, which is a separate step.

Japan also has conditional, time-limited approval for certain regenerative products. On 6 March 2026 the MHLW gave conditional, time-limited approval to two iPS cell-derived products: リハート (Cuorips, a heart muscle cell sheet for severe heart failure) and アムシェプリ (Sumitomo Pharma, a dopaminergic progenitor cell product for Parkinson's disease). The conditions include confirming effectiveness through actual treatment within a seven-year period. Approval is therefore not the same as a finished evidence base. For what those approvals mean, read Japan Approves the First iPS Cell-Derived Products.

Approval and insurance listing are not the same as clinic-based treatment. A patient who is offered an iPS-derived treatment at a clinic should ask which of the two routes the treatment follows. A clinic procedure based on its own filed plan is not an approved product, and it should not be presented as one.

What this means for an international patient

Three practical points follow.

Gloved hands in a white lab coat handling a test tube rack beside a microscope and glass flasks under bright pink lighting

First, the cost of a clinic treatment is set by the clinic. Each hospital and clinic sets its own price, and the price reflects its own cost structure and cell processing, not a national schedule. Comparing totals is less useful than comparing what each total includes.

Second, plan the budget as self-pay. A clinic-based cell treatment is generally charged as private care, so the realistic starting point is the full cost of the course. If you have questions about your own insurance, raise them with our advisors before you book.

Third, the costs should be explained in writing. Article 14 of the Act requires the doctor to explain the treatment and obtain the patient's consent, and Article 13 of the Enforcement Regulations requires that explanation and consent to be in writing. The listed items include the costs of the treatment and the availability of other treatments. A good written quote also shows how the price is built up, how many treatments are included, and what happens if treatment is stopped or if complications occur.

A quote should also say whether follow-up visits after you return home are included. Cost comparisons across clinics are hard to make when each quote covers a different scope. A low headline price that leaves out collection, processing or travel is not a lower total cost. Our advisors obtain quotes from the specific hospitals that fit your case, with the scope stated, so that you can compare like with like.

What drives the cost of self-pay care

Clinic prices usually reflect several components. Ask for each one separately:

Two people against a pink background, one in a pink turtleneck gesturing with open palms, the other in a white lab coat with a stethoscope holding a clipboard

  • Consultation and tests, including pre-treatment blood work and infection screening.
  • Cell collection, such as fat or bone marrow harvest, and whether anesthesia or procedure room fees are included.
  • Cell processing, including culture time, the number of cells, and quality testing.
  • Administration, including the number of treatments and the route, and whether hospital stay or observation is needed.
  • Follow-up, including check-ups after you return home and how the cost of treating a reaction is handled.
  • Travel-related costs, including flights and accommodation. These are usually not part of the medical fee.

For an autologous adipose-derived stem cell course, the number of trips matters too: such a course typically runs about 6 to 12 months, with regular trips to Japan, and the doctor sets the actual plan. Clients who travel with our coordination usually enter Japan for a short-term stay and handle their own visa; an advisor tells you what to prepare.

Our advisors work directly with Japanese hospitals and clinics, match you with a suitable doctor and hospital, and arrange medical record translation, a remote video consultation, interpretation throughout your visit and follow-up after you return home. Consultation and coordination are free, and we reply within one working day. A Japanese doctor first reviews your medical records to judge whether any treatment is appropriate, and the quote is then based on that hospital's pricing.

Frequently asked questions

What does "self-pay" mean in a Japanese clinic?

It means the treatment is private medical care outside the public insurance system. The clinic sets the price, and the patient pays the whole amount. Most clinic-based stem cell treatments are self-pay.

Can part of a stem cell treatment be covered by Japanese insurance?

Plan on paying for the treatment yourself: clinic-based stem cell treatments are generally charged as self-pay, and the rules on combining insured and uninsured care are complex. Ask for an itemized quote that shows which items, if any, are handled differently.

What does a filed provision plan tell me about cost?

A filed provision plan tells you about the safety review, not the price. The Act's stated purpose is to secure the safety of regenerative medicine and promote its prompt, safe provision, and the plan covers the treatment, facility and cell processing; the price is set by the clinic and explained to you in writing before consent. To confirm that a clinic has filed a plan, send the clinic's name to our advisors and we will check whether it has filed a provision plan for that treatment.

If an iPS product is approved, will insurance pay for it?

Approved products may be considered for insurance listing, which is a separate step. The fact that a product is approved does not by itself mean that a clinic's separate iPS-based procedure is covered. Ask which route your treatment follows.

Sources: Act on the Safety of Regenerative Medicine, Articles 1, 2, 4 and 14, and its Enforcement Regulations, Article 13 (e-Gov Law API); Japan Science Portal (JST), report of 18 March 2026 on the conditional approval of two iPS cell-derived products. Checked November 2026; MHLW publications prevail.

Medical disclaimer: This site provides general information only and does not constitute medical advice; whether any treatment is suitable for you must be decided by a doctor after an in-person consultation.